{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:49:06Z","timestamp":1794512946403,"version":"4.9.1"},"reference-count":255,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"fellowship of China Postdoctoral Science Foundation","award":["No. 2023M743967"],"award-info":[{"award-number":["No. 2023M743967"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["No. 2024JJ6684"],"award-info":[{"award-number":["No. 2024JJ6684"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Science Foundation of Xiangya Hospital","award":["No. 2023Q20"],"award-info":[{"award-number":["No. 2023Q20"]}]},{"name":"Natural Science Foundation of Changsha","award":["No. kq2403025"],"award-info":[{"award-number":["No. kq2403025"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2022YFC2504700"],"award-info":[{"award-number":["No. 2022YFC2504700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Program of National Natural Science Foundation of China","award":["No. 82130090"],"award-info":[{"award-number":["No. 82130090"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019092","name":"Science Fund for Distinguished Young Scholars of Hunan Province","doi-asserted-by":"publisher","award":["No. 2023JJ10096"],"award-info":[{"award-number":["No. 2023JJ10096"]}],"id":[{"id":"10.13039\/501100019092","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Program of Hunan Province","award":["No. 2022RC1215"],"award-info":[{"award-number":["No. 2022RC1215"]}]},{"name":"key Program of National Natural Science Foundation of China","award":["U22A20329"],"award-info":[{"award-number":["U22A20329"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Central South University Research Programme of Advanced Interdisciplinary Studies","award":["2023QYJC004"],"award-info":[{"award-number":["2023QYJC004"]}],"id":[{"id":"https:\/\/ror.org\/00f1zfq44","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Scientific Research Program of FuRong Laboratory","award":["No. 2023SK2095"],"award-info":[{"award-number":["No. 2023SK2095"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the notable success of cancer immunotherapy, its effectiveness is often limited in a significant proportion of patients, highlighting the need to explore alternative tumor immune evasion mechanisms. Adenosine, a key metabolite accumulating in hypoxic tumor regions, has emerged as a promising target in oncology. Inhibiting the adenosinergic pathway not only inhibits tumor progression but also holds potential to enhance immunotherapy outcomes. Multiple therapeutic strategies targeting this pathway are being explored, ranging from preclinical studies to clinical trials. This review examines the complex interactions between adenosine, its receptors, and the tumor microenvironment, proposing strategies to target the adenosinergic axis to boost anti-tumor immunity. It also evaluates early clinical data on pharmacological inhibitors of the adenosinergic pathway and discusses future directions for improving clinical responses.<\/jats:p>","DOI":"10.1186\/s40364-025-00784-0","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:41:29Z","timestamp":1747658489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["The progress and prospects of targeting the adenosine pathway in cancer immunotherapy"],"prefix":"10.1186","volume":"13","author":[{"given":"Yuying","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"11","key":"784_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy [J]. Nat Rev Cancer. 2020;20(11):662\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"6024","key":"784_CR2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion [J]. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"key":"784_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semcancer.2019.12.018","volume":"72","author":"CN Baxevanis","year":"2021","unstructured":"Baxevanis CN, Fortis SP, Perez SA. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies [J]. Semin Cancer Biol. 2021;72:76\u201389.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"784_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies [J]. Immunity. 2018;48(3):417\u201333.","journal-title":"Immunity"},{"key":"784_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","volume":"33","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer [J]. Annu Rev Immunol. 2015;33:445\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"784_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice [J]. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"784_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","volume":"22","author":"M Yi","year":"2023","unstructured":"Yi M, Li T, Niu M, et al. Exploiting innate immunity for cancer immunotherapy [J]. Mol Cancer. 2023;22(1):187.","journal-title":"Mol Cancer"},{"issue":"1","key":"784_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade [J]. Nat Rev Immunol. 2020;20(1):25\u201339.","journal-title":"Nat Rev Immunol"},{"key":"784_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J]. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"784_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","volume":"88","author":"M Oladejo","year":"2023","unstructured":"Oladejo M, Paulishak W, Wood L. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines [J]. Semin Cancer Biol. 2023;88:81\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"784_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond [J]. J Hematol Oncol. 2021;14(1):45.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"784_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli SP, Berger T, Araujo DV, et al. Beyond immune checkpoint blockade: emerging immunological strategies [J]. Nat Rev Drug Discov. 2021;20(12):899\u2013919.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"784_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall'Olio","year":"2022","unstructured":"Dall\u2019Olio FG, Marabelle A, Caramella C, et al. Tumour burden and efficacy of immune-checkpoint inhibitors [J]. Nat Rev Clin Oncol. 2022;19(2):75\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"784_CR14","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis [J]. Cancer Treat Rev. 2021;92.","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"784_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W, et al. Development of Immunotherapy Combination Strategies in Cancer [J]. Cancer Discov. 2021;11(6):1368\u201397.","journal-title":"Cancer Discov"},{"issue":"4","key":"784_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides M, Cogdill AP, Robbins PB, et al. Hallmarks of Resistance to Immune-Checkpoint Inhibitors [J]. Cancer Immunol Res. 2022;10(4):372\u201383.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"784_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways [J]. Nat Rev Clin Oncol. 2022;19(1):37\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"784_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.annonc.2021.11.008","volume":"33","author":"I Attili","year":"2022","unstructured":"Attili I, Passaro A, de Marinis F. Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials [J]. Ann Oncol. 2022;33(2):119\u201322.","journal-title":"Ann Oncol"},{"issue":"6","key":"784_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors [J]. Nat Rev Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"784_CR20","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud M, Sandoval J, Obeid M, et al. Novel targets for immune-checkpoint inhibition in cancer [J]. Cancer Treat Rev. 2023;120.","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"784_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","volume":"37","author":"PA Borea","year":"2016","unstructured":"Borea PA, Gessi S, Merighi S, et al. Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? [J]. Trends Pharmacol Sci. 2016;37(6):419\u201334.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"784_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","volume":"74","author":"J Api","year":"2022","unstructured":"Api J, Jacobson KA, Muller CE, et al. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update [J]. Pharmacol Rev. 2022;74(2):340\u201372.","journal-title":"Pharmacol Rev."},{"issue":"10","key":"784_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F di Virgilio","year":"2018","unstructured":"di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment [J]. Nat Rev Cancer. 2018;18(10):601\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"784_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tips.2006.02.004","volume":"27","author":"N White","year":"2006","unstructured":"White N, Burnstock G. P2 receptors and cancer [J]. Trends Pharmacol Sci. 2006;27(4):211\u20137.","journal-title":"Trends Pharmacol Sci"},{"issue":"13","key":"784_CR25","doi-asserted-by":"publisher","first-page":"e108130","DOI":"10.15252\/embj.2021108130","volume":"40","author":"O Kepp","year":"2021","unstructured":"Kepp O, Bezu L, Yamazaki T, et al. ATP and cancer immunosurveillance [J]. Embo j. 2021;40(13):e108130.","journal-title":"Embo j"},{"issue":"6866","key":"784_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/414916a","volume":"414","author":"A Ohta","year":"2001","unstructured":"Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage [J]. Nature. 2001;414(6866):916\u201320.","journal-title":"Nature"},{"issue":"12","key":"784_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, et al. Targeting immunosuppressive adenosine in cancer [J]. Nat Rev Cancer. 2017;17(12):765.","journal-title":"Nat Rev Cancer"},{"key":"784_CR28","doi-asserted-by":"crossref","unstructured":"Vigano S, Alatzoglou D, Irving M, et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function [J]. Front Immunol. 2019;10:925.","DOI":"10.3389\/fimmu.2019.00925"},{"issue":"7261","key":"784_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature08296","volume":"461","author":"MR Elliott","year":"2009","unstructured":"Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance [J]. Nature. 2009;461(7261):282-U165.","journal-title":"Nature"},{"issue":"3","key":"784_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","volume":"8","author":"H Zimmermann","year":"2012","unstructured":"Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases [J]. Purinergic Signal. 2012;8(3):437\u2013502.","journal-title":"Purinergic Signal"},{"key":"784_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1146\/annurev-immunol-051116-052406","volume":"37","author":"J Linden","year":"2019","unstructured":"Linden J, Koch-nolte F, Dahl G. Purine Release, Metabolism, and Signaling in the Inflammatory Response [J]. Annu Rev Immunol. 2019;37:325\u201347.","journal-title":"Annu Rev Immunol"},{"issue":"Pt 1","key":"784_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1042\/bj20020439","volume":"367","author":"GG Yegutkin","year":"2002","unstructured":"Yegutkin GG, Henttinen T, Samburski SS, et al. The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells [J]. Biochem J. 2002;367(Pt 1):121\u20138.","journal-title":"Biochem J"},{"key":"784_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3389\/fimmu.2017.00727","volume":"8","author":"H Zhao","year":"2017","unstructured":"Zhao H, Bo C, Kang Y, et al. What Else Can CD39 Tell Us? [J]. Front Immunol. 2017;8:727.","journal-title":"Front Immunol."},{"issue":"9","key":"784_CR34","doi-asserted-by":"publisher","first-page":"e26246","DOI":"10.4161\/onci.26246","volume":"2","author":"AL Horenstein","year":"2013","unstructured":"Horenstein AL, Chillemi A, Zaccarello G, et al. A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes [J]. Oncoimmunology. 2013;2(9):e26246.","journal-title":"Oncoimmunology"},{"issue":"11","key":"784_CR35","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.febslet.2011.04.036","volume":"585","author":"T Vaisitti","year":"2011","unstructured":"Vaisitti T, Audrito V, Serra S, et al. NAD(+)-metabolizing ecto-enzymes shape tumor-host interactions: The chronic lymphocytic leukemia model [J]. FEBS Lett. 2011;585(11):1514\u201320.","journal-title":"FEBS Lett"},{"issue":"1","key":"784_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0925-4439(03)00058-9","volume":"1638","author":"JW Goding","year":"2003","unstructured":"Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase\/phosphodiesterase family [J]. Biochim Biophys Acta. 2003;1638(1):1\u201319.","journal-title":"Biochim Biophys Acta"},{"issue":"39","key":"784_CR37","doi-asserted-by":"publisher","first-page":"27912","DOI":"10.1074\/jbc.M113.474304","volume":"288","author":"H Korekane","year":"2013","unstructured":"Korekane H, Park JY, Matsumoto A, et al. Identification of ectonucleotide pyrophosphatase\/phosphodiesterase 3 (ENPP3) as a regulator of N-acetylglucosaminyltransferase GnT-IX (GnT-Vb) [J]. J Biol Chem. 2013;288(39):27912\u201326.","journal-title":"J Biol Chem"},{"issue":"27","key":"784_CR38","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1523\/JNEUROSCI.0133-13.2013","volume":"33","author":"SE Street","year":"2013","unstructured":"Street SE, Kramer NJ, Walsh PL, et al. Tissue-nonspecific alkaline phosphatase acts redundantly with PAP and NT5E to generate adenosine in the dorsal spinal cord [J]. J Neurosci. 2013;33(27):11314\u201322.","journal-title":"J Neurosci"},{"issue":"1","key":"784_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1096\/fj.00-0268com","volume":"15","author":"GG Yegutkin","year":"2001","unstructured":"Yegutkin GG, Henttinen T, Jalkanen S. Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions [J]. FASEB J. 2001;15(1):251\u201360.","journal-title":"FASEB J"},{"key":"784_CR40","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1038\/srep08425","volume":"5","author":"E Formoso","year":"2015","unstructured":"Formoso E, Limongelli V, Parrinello M. Energetics and structural characterization of the large-scale functional motion of adenylate kinase [J]. Sci Rep. 2015;5:8425.","journal-title":"Sci Rep"},{"issue":"3","key":"784_CR41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","volume":"74","author":"GG Yegutkin","year":"2022","unstructured":"Yegutkin GG, Boison D. ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain [J]. Pharmacol Rev. 2022;74(3):797\u2013822.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"784_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1165\/ajrcmb.26.2.4650","volume":"26","author":"SH Donaldson","year":"2002","unstructured":"Donaldson SH, Picher M, Boucher RC. Secreted and cell-associated adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism on human airway surfaces [J]. Am J Respir Cell Mol Biol. 2002;26(2):209\u201315.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"784_CR43","doi-asserted-by":"crossref","unstructured":"Losenkova K, Zuccarini M, Karikoski M, et al. Compartmentalization of adenosine metabolism in cancer cells and its modulation during acute hypoxia [J]. J Cell Sci. 2020;133(10):jcs241463.","DOI":"10.1242\/jcs.241463"},{"key":"784_CR44","doi-asserted-by":"publisher","first-page":"108300","DOI":"10.1016\/j.pharmthera.2022.108300","volume":"240","author":"T Kaur","year":"2022","unstructured":"Kaur T, Weadick B, Mace TA, et al. Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities [J]. Pharmacol Ther. 2022;240.","journal-title":"Pharmacol Ther."},{"key":"784_CR45","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fphar.2018.00627","volume":"9","author":"M Pastor-Anglada","year":"2018","unstructured":"Pastor-Anglada M, Perez-Torras S. Who Is Who in Adenosine Transport [J]. Front Pharmacol. 2018;9:627.","journal-title":"Front Pharmacol"},{"issue":"1","key":"784_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","volume":"6","author":"Z Huang","year":"2021","unstructured":"Huang Z, Xie N, Illes P, et al. From purines to purinergic signalling: molecular functions and human diseases [J]. Signal Transduct Target Ther. 2021;6(1):162.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"784_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1471-4159.2001.00607.x","volume":"79","author":"S Latini","year":"2001","unstructured":"Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations [J]. J Neurochem. 2001;79(3):463\u201384.","journal-title":"J Neurochem"},{"key":"784_CR48","doi-asserted-by":"crossref","unstructured":"Abt ER, Rashid K, Le TM, et al. Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity [J]. J Clin Invest. 2022;132(16):e160852.","DOI":"10.1172\/JCI160852"},{"key":"784_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2013.00085","volume":"4","author":"G Hasko","year":"2013","unstructured":"Hasko G, Cronstein B. Regulation of inflammation by adenosine [J]. Front Immunol. 2013;4:85.","journal-title":"Front Immunol."},{"issue":"9","key":"784_CR50","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd2638","volume":"7","author":"G Hasko","year":"2008","unstructured":"Hasko G, Linden J, Cronstein B, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases [J]. Nat Rev Drug Discov. 2008;7(9):759\u201370.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"784_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0006-2952(00)00570-0","volume":"61","author":"BB Fredholm","year":"2001","unstructured":"Fredholm BB, Irenius E, Kull B, et al. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells11Abbreviations: cAMP, cyclic adenosine 3\u2032,5\u2032-monophosphate; CHO, Chinese hamster ovary; NBMPR, nitrobenzylthioinosine; and NECA, 5\u2032-N-ethyl carboxamido adenosine [J]. Biochem Pharmacol. 2001;61(4):443\u20138.","journal-title":"Biochem Pharmacol"},{"key":"784_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/B978-0-12-385526-8.00003-5","volume":"61","author":"BB Fredholm","year":"2011","unstructured":"Fredholm BB, Johansson S, Wang YQ. Adenosine and the regulation of metabolism and body temperature [J]. Adv Pharmacol. 2011;61:77\u201394.","journal-title":"Adv Pharmacol"},{"issue":"2","key":"784_CR53","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/ijms15022024","volume":"15","author":"S Sheth","year":"2014","unstructured":"Sheth S, Brito R, Mukherjea D, et al. Adenosine receptors: expression, function and regulation [J]. Int J Mol Sci. 2014;15(2):2024\u201352.","journal-title":"Int J Mol Sci"},{"key":"784_CR54","doi-asserted-by":"crossref","unstructured":"Lillo A, Martinez-Pinilla E, Reyes-Resina I, et al. Adenosine A(2A) and A(3) receptors are able to interact with each other. a further piece in the puzzle of Adenosine receptor-mediated signaling [J]. Int J Mol Sci. 2020;21(14):5070.","DOI":"10.3390\/ijms21145070"},{"issue":"7","key":"784_CR55","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/sj.cdd.4402132","volume":"14","author":"BB Fredholm","year":"2007","unstructured":"Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair [J]. Cell Death Differ. 2007;14(7):1315\u201323.","journal-title":"Cell Death Differ"},{"issue":"3","key":"784_CR56","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","volume":"98","author":"PA Borea","year":"2018","unstructured":"Borea PA, Gessi S, Merighi S, et al. Pharmacology of Adenosine Receptors: The State of the Art [J]. Physiol Rev. 2018;98(3):1591\u2013625.","journal-title":"Physiol Rev"},{"issue":"1","key":"784_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-017-9593-0","volume":"14","author":"G Burnstock","year":"2018","unstructured":"Burnstock G, Knight GE. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression [J]. Purinergic Signal. 2018;14(1):1\u201318.","journal-title":"Purinergic Signal"},{"key":"784_CR58","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1098\/rstb.2015.0427","volume":"371","author":"RA North","year":"2016","unstructured":"North RA. P2X receptors [J]. Philos Trans R Soc Lond B Biol Sci. 2016;371:1700.","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"issue":"5","key":"784_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0306-3623(85)90001-1","volume":"16","author":"G Burnstock","year":"1985","unstructured":"Burnstock G, Kennedy C. Is there a basis for distinguishing 2 types of P2-purinoceptor [J]. Gen Pharmacol. 1985;16(5):433\u201340.","journal-title":"Gen Pharmacol"},{"issue":"8","key":"784_CR60","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy [J]. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"key":"784_CR61","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer [J]. Pharmacol Ther. 2021;221.","journal-title":"Pharmacol Ther."},{"key":"784_CR62","doi-asserted-by":"crossref","unstructured":"Liu L, Nie S, Xie M. Tumor Microenvironment as a New Target for Tumor Immunotherapy of Polysaccharides [J]. Crit Rev Food Sci Nutr. 2016;56 Suppl 1:S85\u201394.","DOI":"10.1080\/10408398.2015.1077191"},{"issue":"1","key":"784_CR63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy [J]. Signal Transduct Target Ther. 2021;6(1):72.","journal-title":"Signal Transduct Target Ther"},{"key":"784_CR64","doi-asserted-by":"crossref","unstructured":"Yang H, Lei MML, Xie L, et al. Deciphering adenosine signaling in hepatocellular carcinoma: pathways, prognostic models, and therapeutic implications [J]. Clin Mol Hepatol. 2025;31(1):1-15.","DOI":"10.3350\/cmh.2024.1068"},{"key":"784_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biochi.2020.06.001","volume":"176","author":"A Soleimani","year":"2020","unstructured":"Soleimani A, Farshchi HK, Mirzavi F, et al. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma [J]. Biochimie. 2020;176:21\u201330.","journal-title":"Biochimie"},{"issue":"3","key":"784_CR66","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu H, Kuang X, Zhang Y, et al. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis [J]. Cancer Cell. 2020;37(3):324-39 e8.","journal-title":"Cancer Cell."},{"issue":"12","key":"784_CR67","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/iub.2905","volume":"76","author":"D Pietrobono","year":"2024","unstructured":"Pietrobono D, Russo L, Bertilacchi MS, et al. Extracellular adenosine oppositely regulates the purinome machinery in glioblastoma and mesenchymal stem cells [J]. IUBMB Life. 2024;76(12):1234\u201351.","journal-title":"IUBMB Life"},{"issue":"12","key":"784_CR68","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, et al. Targeting immunosuppressive adenosine in cancer [J]. Nat Rev Cancer. 2017;17(12):709\u201324.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"784_CR69","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.4049\/jimmunol.177.10.7173","volume":"177","author":"S Morello","year":"2006","unstructured":"Morello S, Ito K, Yamamura S, et al. IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter [J]. J Immunol. 2006;177(10):7173\u201383.","journal-title":"J Immunol"},{"issue":"1","key":"784_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation [J]. Nat Rev Immunol. 2020;20(1):55\u201370.","journal-title":"Nat Rev Immunol"},{"key":"784_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C. Cytokine Regulation and Function in T Cells [J]. Annu Rev Immunol. 2021;39:51\u201376.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"784_CR72","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1021\/acs.accounts.0c00486","volume":"53","author":"K Lei","year":"2020","unstructured":"Lei K, Kurum A, Tang L. Mechanical Immunoengineering of T cells for Therapeutic Applications [J]. Acc Chem Res. 2020;53(12):2777\u201390.","journal-title":"Acc Chem Res"},{"issue":"8","key":"784_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.it.2016.06.005","volume":"37","author":"V Mayya","year":"2016","unstructured":"Mayya V, Dustin ML. What Scales the T Cell Response? [J]. Trends Immunol. 2016;37(8):513\u201322.","journal-title":"Trends Immunol"},{"issue":"6","key":"784_CR74","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.smim.2012.12.006","volume":"24","author":"KC Verbist","year":"2012","unstructured":"Verbist KC, Wang R, Green DR. T cell metabolism and the immune response [J]. Semin Immunol. 2012;24(6):399\u2013404.","journal-title":"Semin Immunol"},{"key":"784_CR75","doi-asserted-by":"publisher","first-page":"104216","DOI":"10.1016\/j.ebiom.2022.104216","volume":"83","author":"NK Verma","year":"2022","unstructured":"Verma NK, Wong BHS, Poh ZS, et al. Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint [J]. EBioMed. 2022;83.","journal-title":"EBioMed."},{"issue":"1","key":"784_CR76","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","volume":"7","author":"B Mastelic-Gavillet","year":"2019","unstructured":"Mastelic-Gavillet B, Navarro Rodrigo B, D\u00e9combaz L, et al. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells [J]. J Immunother Cancer. 2019;7(1):257.","journal-title":"J Immunother Cancer."},{"issue":"2","key":"784_CR77","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4049\/jimmunol.174.2.1073","volume":"174","author":"CM Lappas","year":"2005","unstructured":"Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells [J]. J Immunol. 2005;174(2):1073\u201380.","journal-title":"J Immunol"},{"issue":"10","key":"784_CR78","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1074\/jbc.M112.408765","volume":"288","author":"G Rodriguez","year":"2013","unstructured":"Rodriguez G, Ross JA, Nagy ZS, et al. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex [J]. J Biol Chem. 2013;288(10):7137\u201346.","journal-title":"J Biol Chem"},{"key":"784_CR79","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fimmu.2016.00222","volume":"7","author":"WVL Wehbi","year":"2016","unstructured":"Wehbi WVL, Task\u00e9n K. Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units [J]. Front Immunol. 2016;7:222.","journal-title":"Front Immunol."},{"issue":"9","key":"784_CR80","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.4049\/jimmunol.0901247","volume":"183","author":"A Ohta","year":"2009","unstructured":"Ohta A, Ohta A, Madasu M, et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments [J]. J Immunol. 2009;183(9):5487\u201393.","journal-title":"J Immunol"},{"issue":"1","key":"784_CR81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","volume":"16","author":"SR Ma","year":"2017","unstructured":"Ma SR, Deng WW, Liu JF, et al. Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma [J]. Mol Cancer. 2017;16(1):99.","journal-title":"Mol Cancer"},{"key":"784_CR82","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","volume":"3","author":"A Ohta","year":"2012","unstructured":"Ohta A, Kini R, Ohta A, et al. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway [J]. Front Immunol. 2012;3:190.","journal-title":"Front Immunol."},{"issue":"5","key":"784_CR83","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","volume":"19","author":"KL O'Brien","year":"2019","unstructured":"O\u2019Brien KL, Finlay DK. Immunometabolism and natural killer cell responses [J]. Nat Rev Immunol. 2019;19(5):282\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"8000","key":"784_CR84","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, et al. Natural killer cell therapies [J]. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"1","key":"784_CR85","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, et al. Natural killer cells in cancer biology and therapy [J]. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"issue":"10","key":"784_CR86","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, et al. The adenosine pathway in immuno-oncology [J]. Nat Rev Clin Oncol. 2020;17(10):611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"784_CR87","doi-asserted-by":"publisher","first-page":"7758","DOI":"10.1158\/0008-5472.CAN-06-0478","volume":"66","author":"A Lokshin","year":"2006","unstructured":"Lokshin A, Raskovalova T, Huang X, et al. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells [J]. Cancer Res. 2006;66(15):7758\u201365.","journal-title":"Cancer Res"},{"issue":"1","key":"784_CR88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nri.2016.116","volume":"17","author":"T Worbs","year":"2017","unstructured":"Worbs T, Hammerschmidt SI, F\u00f6rster R. Dendritic cell migration in health and disease [J]. Nat Rev Immunol. 2017;17(1):30\u201348.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"784_CR89","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/cmi.2014.130","volume":"12","author":"Y Liu","year":"2015","unstructured":"Liu Y, Cao X. Intratumoral dendritic cells in the anti-tumor immune response [J]. Cell Mol Immunol. 2015;12(4):387\u201390.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"784_CR90","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells [J]. Nat Rev Cancer. 2012;12(4):265\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"784_CR91","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2008-02-136325","volume":"112","author":"SV Novitskiy","year":"2008","unstructured":"Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function [J]. Blood. 2008;112(5):1822\u201331.","journal-title":"Blood"},{"issue":"12","key":"784_CR92","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.4049\/jimmunol.1900765","volume":"203","author":"M Kayhan","year":"2019","unstructured":"Kayhan M, Koyas A, Akdemir I, et al. Adenosine Receptor Signaling Targets Both PKA and Epac Pathways to Polarize Dendritic Cells to a Suppressive Phenotype [J]. J Immunol. 2019;203(12):3247\u201355.","journal-title":"J Immunol"},{"issue":"4","key":"784_CR93","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/imm.12053","volume":"138","author":"J Challier","year":"2013","unstructured":"Challier J, Bruniquel D, Sewell AK, et al. Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity [J]. Immunology. 2013;138(4):402\u201310.","journal-title":"Immunology"},{"issue":"2","key":"784_CR94","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","volume":"99","author":"PX Liew","year":"2019","unstructured":"Liew PX, Kubes P. The Neutrophil\u2019s Role During Health and Disease [J]. Physiol Rev. 2019;99(2):1223\u201348.","journal-title":"Physiol Rev"},{"issue":"2","key":"784_CR95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/0003-4819-109-2-127","volume":"109","author":"RI Lehrer","year":"1988","unstructured":"Lehrer RI, Ganz T, Selsted ME, et al. Neutrophils and host defense [J]. Ann Intern Med. 1988;109(2):127\u201342.","journal-title":"Ann Intern Med"},{"issue":"4","key":"784_CR96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","volume":"134","author":"C Carmona-Rivera","year":"2019","unstructured":"Carmona-Rivera C, Khaznadar SS, Shwin KW, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2 [J]. Blood. 2019;134(4):395\u2013406.","journal-title":"Blood"},{"issue":"1","key":"784_CR97","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41467-019-09801-x","volume":"10","author":"RA Ali","year":"2019","unstructured":"Ali RA, Gandhi AA, Meng H, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome [J]. Nat Commun. 2019;10(1):1916.","journal-title":"Nat Commun"},{"issue":"1","key":"784_CR98","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1152\/physrev.00062.2021","volume":"103","author":"M Herre","year":"2023","unstructured":"Herre M, Cedervall J, Mackman N, et al. Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases [J]. Physiol Rev. 2023;103(1):277\u2013312.","journal-title":"Physiol Rev"},{"issue":"4","key":"784_CR99","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.immuni.2005.10.001","volume":"23","author":"A Mantovani","year":"2005","unstructured":"Mantovani A, Sica A, Locati M. Macrophage polarization comes of age [J]. Immunity. 2005;23(4):344\u20136.","journal-title":"Immunity"},{"issue":"11","key":"784_CR100","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes [J]. Trends Immunol. 2002;23(11):549\u201355.","journal-title":"Trends Immunol"},{"issue":"3","key":"784_CR101","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41423-020-00541-3","volume":"18","author":"DM Mosser","year":"2021","unstructured":"Mosser DM, Hamidzadeh K, Goncalves R. Macrophages and the maintenance of homeostasis [J]. Cell Mol Immunol. 2021;18(3):579\u201387.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"784_CR102","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.semcancer.2012.02.002","volume":"22","author":"A Schmieder","year":"2012","unstructured":"Schmieder A, Michel J, Sch\u00f6nhaar K, et al. Differentiation and gene expression profile of tumor-associated macrophages [J]. Semin Cancer Biol. 2012;22(4):289\u201397.","journal-title":"Semin Cancer Biol"},{"key":"784_CR103","doi-asserted-by":"crossref","unstructured":"Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, et al. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages [J]. Biomaterials. 2021;278:121137.","DOI":"10.1016\/j.biomaterials.2021.121137"},{"issue":"6","key":"784_CR104","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.7150\/thno.30716","volume":"9","author":"P Wang","year":"2019","unstructured":"Wang P, Wang H, Huang Q, et al. Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation [J]. Theranostics. 2019;9(6):1714\u201327.","journal-title":"Theranostics"},{"issue":"1","key":"784_CR105","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1096\/fj.11-190934","volume":"26","author":"B Cs\u00f3ka","year":"2012","unstructured":"Cs\u00f3ka B, Selmeczy Z, Koscs\u00f3 B, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors [J]. Faseb j. 2012;26(1):376\u201386.","journal-title":"Faseb j"},{"key":"784_CR106","doi-asserted-by":"crossref","unstructured":"Graziano V, Dannhorn A, Hulme H, et al. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma [J]. J Immunother Cancer. 2023;11(8):e006457.","DOI":"10.1136\/jitc-2022-006457"},{"key":"784_CR107","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy [J]. Front Immunol. 2022;13.","journal-title":"Front Immunol."},{"issue":"5","key":"784_CR108","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity [J]. Immunity. 2021;54(5):875\u201384.","journal-title":"Immunity"},{"issue":"3","key":"784_CR109","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, et al. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment [J]. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"2","key":"784_CR110","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay kurt FG, Arkhypo VI, et al. Myeloid-derived suppressor cells in cancer and cancer therapy [J]. Nat Rev Clin Oncol. 2024;21(2):147\u201364.","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"784_CR111","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer [J]. Signal Transduct Target Ther. 2021;6(1):362.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"784_CR112","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-019-0797-3","volume":"12","author":"M Lv","year":"2019","unstructured":"Lv M, Wang K, Huang XJ. Myeloid-derived suppressor cells in hematological malignancies: friends or foes [J]. J Hematol Oncol. 2019;12(1):105.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"784_CR113","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age [J]. Nat Immunol. 2018;19(2):108\u201319.","journal-title":"Nat Immunol"},{"issue":"1","key":"784_CR114","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy [J]. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"issue":"1","key":"784_CR115","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-0843-1","volume":"13","author":"Z Yang","year":"2020","unstructured":"Yang Z, Guo J, Weng L, et al. Myeloid-derived suppressor cells-new and exciting players in lung cancer [J]. J Hematol Oncol. 2020;13(1):10.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"784_CR116","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","volume":"74","author":"C Cekic","year":"2014","unstructured":"Cekic C, Day YJ, Sag D, et al. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment [J]. Cancer Res. 2014;74(24):7250\u20139.","journal-title":"Cancer Res"},{"issue":"29","key":"784_CR117","doi-asserted-by":"publisher","first-page":"27478","DOI":"10.18632\/oncotarget.4393","volume":"6","author":"C Sorrentino","year":"2015","unstructured":"Sorrentino C, Miele L, Porta A, et al. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model [J]. Oncotarget. 2015;6(29):27478\u201389.","journal-title":"Oncotarget"},{"issue":"5","key":"784_CR118","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/2326-6066.CIR-22-0658","volume":"11","author":"X Xia","year":"2023","unstructured":"Xia X, Mao Z, Wang W, et al. Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer [J]. Cancer Immunol Res. 2023;11(5):600\u201313.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"784_CR119","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","volume":"20","author":"AK Moesta","year":"2020","unstructured":"Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer [J]. Nat Rev Immunol. 2020;20(12):739\u201355.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"784_CR120","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, et al. CD39\/CD73\/A2AR pathway and cancer immunotherapy [J]. Mol Cancer. 2023;22(1):44.","journal-title":"Mol Cancer"},{"issue":"1","key":"784_CR121","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1038\/s41467-023-38578-3","volume":"14","author":"T Tang","year":"2023","unstructured":"Tang T, Huang X, Lu M, et al. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner [J]. Nat Commun. 2023;14(1):3364.","journal-title":"Nat Commun"},{"issue":"7","key":"784_CR122","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/0008-5472.CAN-23-0268","volume":"83","author":"K Delgiorno","year":"2023","unstructured":"Delgiorno K. CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer [J]. Cancer Res. 2023;83(7):977\u20138.","journal-title":"Cancer Res"},{"key":"784_CR123","doi-asserted-by":"publisher","first-page":"115225","DOI":"10.1016\/j.biopha.2023.115225","volume":"165","author":"C Giraulo","year":"2023","unstructured":"Giraulo C, Turiello R, Orlando L, et al. The CD73 is induced by TGF-\u03b21 triggered by nutrient deprivation and highly expressed in dedifferentiated human melanoma [J]. Biomed Pharmacother. 2023;165:115225.","journal-title":"Biomed Pharmacother."},{"issue":"6","key":"784_CR124","doi-asserted-by":"publisher","first-page":"e2206335","DOI":"10.1002\/advs.202206335","volume":"10","author":"W Liu","year":"2023","unstructured":"Liu W, Yu X, Yuan Y, et al. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism [J]. Adv Sci (Weinh). 2023;10(6):e2206335.","journal-title":"Adv Sci (Weinh)"},{"key":"784_CR125","doi-asserted-by":"crossref","unstructured":"Allard D, Cousineau I, Ma EH, et al. The CD73 immune checkpoint promotes tumor cell metabolic fitness [J]. Elife. 2023;12:e84508.","DOI":"10.7554\/eLife.84508"},{"issue":"3","key":"784_CR126","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.cmr.0000215030.69823.11","volume":"16","author":"R Sadej","year":"2006","unstructured":"Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5\u2019-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma [J]. Melanoma Res. 2006;16(3):213\u201322.","journal-title":"Melanoma Res"},{"issue":"4","key":"784_CR127","doi-asserted-by":"publisher","first-page":"647","DOI":"10.18388\/abp.2012_2105","volume":"59","author":"R Sadej","year":"2012","unstructured":"Sadej R, Skladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5 \u2019-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells [J]. Acta Biochim Pol. 2012;59(4):647\u201352.","journal-title":"Acta Biochim Pol"},{"key":"784_CR128","doi-asserted-by":"crossref","unstructured":"Iser IC, Vedovatto S, Oliveira FD, Beckenkamp LR, Lenz G, Wink MR. The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer [J]. Semin Cancer Biol, 2022;86(Pt 2):202\u2013213.","DOI":"10.1016\/j.semcancer.2022.06.012"},{"issue":"1","key":"784_CR129","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-019-0724-7","volume":"12","author":"XL Ma","year":"2019","unstructured":"Ma XL, Shen MN, Hu B, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K\/AKT signaling by inducing Rap1-mediated membrane localization of P110\u03b2 and predicts poor prognosis [J]. J Hematol Oncol. 2019;12(1):37.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"784_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13045-020-0845-z","volume":"13","author":"XL Ma","year":"2020","unstructured":"Ma XL, Hu B, Tang WG, et al. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma [J]. J Hematol Oncol. 2020;13(1):11.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"784_CR131","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1002\/1878-0261.13046","volume":"15","author":"MG Terp","year":"2021","unstructured":"Terp MG, Gammelgaard OL, Vever H, et al. Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes [J]. Mol Oncol. 2021;15(12):3299\u2013316.","journal-title":"Mol Oncol"},{"issue":"15","key":"784_CR132","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jcmm.17802","volume":"27","author":"L Chi","year":"2023","unstructured":"Chi L, Huan L, Zhang C, et al. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling [J]. J Cell Mol Med. 2023;27(15):2150\u201364.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"784_CR133","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.7150\/thno.70581","volume":"12","author":"J Lan","year":"2022","unstructured":"Lan J, Wei G, Liu J, et al. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness [J]. Theranostics. 2022;12(6):2598\u2013612.","journal-title":"Theranostics"},{"issue":"2","key":"784_CR134","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10555-007-9054-2","volume":"26","author":"D Lukashev","year":"2007","unstructured":"Lukashev D, Ohta A, Sitkovsky M. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues [J]. Cancer Metastasis Rev. 2007;26(2):273\u20139.","journal-title":"Cancer Metastasis Rev"},{"issue":"41","key":"784_CR135","doi-asserted-by":"publisher","first-page":"E9640","DOI":"10.1073\/pnas.1809695115","volume":"115","author":"J Lan","year":"2018","unstructured":"Lan J, Lu H, Samanta D, et al. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment [J]. Proc Natl Acad Sci U S A. 2018;115(41):E9640\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"784_CR136","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts [J]. Nat Rev Clin Oncol. 2021;18(12):792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"784_CR137","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts [J]. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"784_CR138","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer [J]. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"784_CR139","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41467-019-14060-x","volume":"11","author":"M Yu","year":"2020","unstructured":"Yu M, Guo G, Huang L, et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint [J]. Nat Commun. 2020;11(1):515.","journal-title":"Nat Commun"},{"issue":"1","key":"784_CR140","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts [J]. Physiol Rev. 2021;101(1):147\u201376.","journal-title":"Physiol Rev"},{"issue":"2","key":"784_CR141","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts [J]. Nat Rev Drug Discov. 2019;18(2):99\u2013115.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"784_CR142","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: Perspectives and challenges [J]. Cancer Cell. 2023;41(3):434\u201349.","journal-title":"Cancer Cell"},{"issue":"21","key":"784_CR143","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","volume":"75","author":"M Turcotte","year":"2015","unstructured":"Turcotte M, Spring K, Pommey S, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer [J]. Cancer Res. 2015;75(21):4494\u2013503.","journal-title":"Cancer Res"},{"issue":"3","key":"784_CR144","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-dahirel A, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer [J]. Cancer Cell. 2018;33(3):463-79 e10.","journal-title":"Cancer Cell."},{"issue":"39","key":"784_CR145","doi-asserted-by":"publisher","first-page":"64274","DOI":"10.18632\/oncotarget.11729","volume":"7","author":"C Sorrentino","year":"2016","unstructured":"Sorrentino C, Miele L, Porta A, et al. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression [J]. Oncotarget. 2016;7(39):64274\u201388.","journal-title":"Oncotarget"},{"issue":"10","key":"784_CR146","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1158\/2326-6066.CIR-19-0923","volume":"8","author":"G Hu","year":"2020","unstructured":"Hu G, Cheng P, Pan J, et al. An IL6-Adenosine Positive Feedback Loop between CD73(+) \u03b3\u03b4Tregs and CAFs Promotes Tumor Progression in Human Breast Cancer [J]. Cancer Immunol Res. 2020;8(10):1273\u201386.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"784_CR147","doi-asserted-by":"publisher","first-page":"1940675","DOI":"10.1080\/2162402X.2021.1940675","volume":"10","author":"RA O'Connor","year":"2021","unstructured":"O\u2019Connor RA, Chauhan V, Mathieson L, et al. T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer [J]. Oncoimmunology. 2021;10(1):1940675.","journal-title":"Oncoimmunology"},{"issue":"8","key":"784_CR148","doi-asserted-by":"publisher","first-page":"e1208875","DOI":"10.1080\/2162402X.2016.1208875","volume":"5","author":"CM Hay","year":"2016","unstructured":"Hay CM, Sult E, Huang Q, et al. Targeting CD73 in the tumor microenvironment with MEDI9447 [J]. Oncoimmunology. 2016;5(8):e1208875.","journal-title":"Oncoimmunology"},{"key":"784_CR149","doi-asserted-by":"crossref","unstructured":"Overman MJ, Lorusso P, Strickler JH, et al. Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc) [J]. J Clin Oncol. 2018;36(15_suppl):4123.","DOI":"10.1200\/JCO.2018.36.15_suppl.4123"},{"key":"784_CR150","doi-asserted-by":"crossref","unstructured":"Bendell JC, Lorusso P, Overman MJ, et al. Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab +\/- durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC) [J]. J Clin Oncol. 2021;39(15_suppl):9047.","DOI":"10.1200\/JCO.2021.39.15_suppl.9047"},{"issue":"7","key":"784_CR151","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, Lorusso P, Overman M, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors [J]. Cancer Immunol Immunother. 2023;72(7):2443\u201358.","journal-title":"Cancer Immunol Immunother"},{"key":"784_CR152","doi-asserted-by":"crossref","unstructured":"Siu LL, Burris H, Le D T, et al. Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors [J]. Cancer Res. 2018;78(13_suppl):CT180.","DOI":"10.1158\/1538-7445.AM2018-CT180"},{"key":"784_CR153","doi-asserted-by":"crossref","unstructured":"Luke JJ, Powderly JD, Merchan JR, et al. Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers [J]. J Clin Oncol. 2019;37(15_suppl):TPS2654.","DOI":"10.1200\/JCO.2019.37.15_suppl.2505"},{"issue":"1","key":"784_CR154","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41408-024-01019-5","volume":"14","author":"A Ray","year":"2024","unstructured":"Ray A, Du T, Wan X, et al. A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death [J]. Blood Cancer J. 2024;14(1):58.","journal-title":"Blood Cancer J"},{"issue":"11","key":"784_CR155","doi-asserted-by":"publisher","first-page":"9447","DOI":"10.1021\/acs.jmedchem.4c00553","volume":"67","author":"S Wang","year":"2024","unstructured":"Wang S, Kong Z, Shi Y, et al. Discovery of Small and Bifunctional Molecules Targeting PD-L1\/CD73 for Cancer Dual Immunotherapy [J]. J Med Chem. 2024;67(11):9447\u201364.","journal-title":"J Med Chem"},{"issue":"18","key":"784_CR156","doi-asserted-by":"publisher","first-page":"10433","DOI":"10.1021\/acs.jmedchem.0c01086","volume":"63","author":"XH Du","year":"2020","unstructured":"Du XH, Moore J, Blank BR, et al. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production [J]. J Med Chem. 2020;63(18):10433\u201359.","journal-title":"J Med Chem"},{"issue":"20","key":"784_CR157","doi-asserted-by":"publisher","first-page":"11448","DOI":"10.1021\/acs.jmedchem.0c00525","volume":"63","author":"KV Lawson","year":"2020","unstructured":"Lawson KV, Kalisiak J, Lindsey EA, et al. Discovery of AB680: A Potent and Selective Inhibitor of CD73 [J]. J Med Chem. 2020;63(20):11448\u201368.","journal-title":"J Med Chem"},{"issue":"648","key":"784_CR158","doi-asserted-by":"publisher","first-page":"eabh1261","DOI":"10.1126\/scitranslmed.abh1261","volume":"14","author":"C Mao","year":"2022","unstructured":"Mao C, Yeh S, Fu J, et al. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression [J]. Sci Transl Med. 2022;14(648):eabh1261.","journal-title":"Sci Transl Med."},{"issue":"2","key":"784_CR159","doi-asserted-by":"publisher","first-page":"e2097","DOI":"10.1038\/cddis.2015.411","volume":"7","author":"AD Garg","year":"2016","unstructured":"Garg AD, Krysko DV, Vandenabeele P, et al. Extracellular ATP and P\u2082X\u2087 receptor exert context-specific immunogenic effects after immunogenic cancer cell death [J]. Cell Death Dis. 2016;7(2):e2097.","journal-title":"Cell Death Dis"},{"issue":"2","key":"784_CR160","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-022-01794-9","volume":"37","author":"M Casey","year":"2023","unstructured":"Casey M, Segawa K, Law SC, et al. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma [J]. Leukemia. 2023;37(2):379\u201387.","journal-title":"Leukemia"},{"key":"784_CR161","doi-asserted-by":"crossref","unstructured":"Wang WB, Hu D W, Feng YQ, et al. Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome [J]. BMC Biol. 2020;18(1):182.","DOI":"10.1186\/s12915-020-00918-w"},{"issue":"3","key":"784_CR162","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.cmet.2020.07.016","volume":"32","author":"A Hooftman","year":"2020","unstructured":"Hooftman A, Angiari S, Hester S, et al. The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation [J]. Cell Metab. 2020;32(3):468-78.e7.","journal-title":"Cell Metab"},{"issue":"5","key":"784_CR163","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","volume":"22","author":"BR Sharma","year":"2021","unstructured":"Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases [J]. Nat Immunol. 2021;22(5):550\u20139.","journal-title":"Nat Immunol"},{"key":"784_CR164","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu J, Wu H. Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation [J]. Annu Rev Immunol. 2023;41:301\u201316.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"784_CR165","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","volume":"9","author":"XY Li","year":"2019","unstructured":"Li XY, Moesta AK, Xiao C, et al. Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity [J]. Cancer Discovery. 2019;9(12):1754\u201373.","journal-title":"Cancer Discovery."},{"issue":"2","key":"784_CR166","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","volume":"24","author":"PDA Vignali","year":"2023","unstructured":"Vignali PDA, Depeaux K, Watson MJ, et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity [J]. Nat Immunol. 2023;24(2):267\u201379.","journal-title":"Nat Immunol"},{"issue":"3","key":"784_CR167","first-page":"74","volume":"8","author":"D Chandra","year":"2020","unstructured":"Chandra D, Barbon CM, Borodovsky A, et al. The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+dendritic cells [J]. Cancer Immunol Res. 2020;8(3):74\u20135.","journal-title":"Cancer Immunol Res"},{"issue":"13_Supplement","key":"784_CR168","doi-asserted-by":"publisher","first-page":"LB-192-LB-","DOI":"10.1158\/1538-7445.AM2019-LB-192","volume":"79","author":"CM Barbon","year":"2019","unstructured":"Barbon CM, Borodovsky A, Wang Y, et al. Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells [J]. Cancer Res. 2019;79(13_Supplement):LB-192-LB-.","journal-title":"Cancer Res."},{"issue":"7","key":"784_CR169","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neo.2017.02.004","volume":"19","author":"M Mediavilla-Varela","year":"2017","unstructured":"Mediavilla-Varela M, Castro J, Chiappori A, et al. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment [J]. Neoplasia. 2017;19(7):530\u20136.","journal-title":"Neoplasia"},{"issue":"11","key":"784_CR170","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-21-2742","volume":"28","author":"AA Chiappori","year":"2022","unstructured":"Chiappori AA, Creelan B, Tanvetyanon T, et al. Phase I Study of Taminadenant (PBF509\/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer [J]. Clin Cancer Res. 2022;28(11):2313\u201320.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"784_CR171","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong L, Hotson A, Powderly JD, et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer [J]. Cancer Discov. 2020;10(1):40\u201353.","journal-title":"Cancer Discov"},{"issue":"9","key":"784_CR172","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","volume":"26","author":"B Sidders","year":"2020","unstructured":"Sidders B, Zhang P, Goodwin K, et al. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response [J]. Clin Cancer Res. 2020;26(9):2176\u201387.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"784_CR173","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-16-0544","volume":"76","author":"D Mittal","year":"2016","unstructured":"Mittal D, Sinha D, Barkauskas D, et al. Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis [J]. Cancer Res. 2016;76(15):4372\u201382.","journal-title":"Cancer Res"},{"issue":"8","key":"784_CR174","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-19-0833","volume":"8","author":"S Chen","year":"2020","unstructured":"Chen S, Akdemir I, Fan J, et al. The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8(+) T-cell Responses and Promotes Tumor Growth [J]. Cancer Immunol Res. 2020;8(8):1064\u201374.","journal-title":"Cancer Immunol Res"},{"key":"784_CR175","doi-asserted-by":"publisher","first-page":"100824","DOI":"10.1016\/j.neo.2022.100824","volume":"32","author":"S Guan","year":"2022","unstructured":"Guan S, Suman S, Amann JM, et al. Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy [J]. Neoplasia. 2022;32.","journal-title":"Neoplasia."},{"key":"784_CR176","doi-asserted-by":"crossref","unstructured":"Tay AHM, Prieto-D\u00edaz R, Neo S, et al. A(2B) adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models [J]. J Immunother Cancer. 2022;10(5):e004592.","DOI":"10.1136\/jitc-2022-004592"},{"key":"784_CR177","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-med-060619-023155","volume":"72","author":"EA Thompson","year":"2021","unstructured":"Thompson EA, Powell JD. Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches [J]. Annu Rev Med. 2021;72:331\u201348.","journal-title":"Annu Rev Med"},{"issue":"11","key":"784_CR178","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/jnci\/djad091","volume":"115","author":"JV Evans","year":"2023","unstructured":"Evans JV, Suman S, Goruganthu MUL, et al. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression [J]. J Natl Cancer Inst. 2023;115(11):1404\u201319.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"784_CR179","doi-asserted-by":"publisher","first-page":"1824643","DOI":"10.1080\/2162402X.2020.1824643","volume":"9","author":"N Li","year":"2020","unstructured":"Li N, Tang N, Cheng C, et al. Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway [J]. Oncoimmunology. 2020;9(1):1824643.","journal-title":"Oncoimmunology"},{"issue":"1","key":"784_CR180","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.CIR-22-0260","volume":"11","author":"C Jacoberger-Foissac","year":"2023","unstructured":"Jacoberger-Foissac C, Cousineau I, Bareche Y, et al. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer [J]. Cancer Immunol Res. 2023;11(1):56\u201371.","journal-title":"Cancer Immunol Res"},{"issue":"85","key":"784_CR181","doi-asserted-by":"publisher","first-page":"eabq3015","DOI":"10.1126\/sciimmunol.abq3015","volume":"8","author":"J Stagg","year":"2023","unstructured":"Stagg J, Golden E, Wennerberg E, et al. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy [J]. Sci Immunol. 2023;8(85):eabq3015.","journal-title":"Sci Immunol."},{"issue":"10","key":"784_CR182","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","volume":"60","author":"SFM Haeusler","year":"2011","unstructured":"Haeusler SFM, del Barrio IM, Strohschein J, et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity [J]. Cancer Immunol Immunother. 2011;60(10):1405\u201318.","journal-title":"Cancer Immunol Immunother"},{"key":"784_CR183","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fimmu.2017.00897","volume":"8","author":"BA Rader","year":"2017","unstructured":"Rader BA. Alkaline Phosphatase, an Unconventional Immune Protein [J]. Front Immunol. 2017;8:897.","journal-title":"Front Immunol"},{"issue":"1","key":"784_CR184","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuron.2008.08.024","volume":"60","author":"MJ Zylka","year":"2008","unstructured":"Zylka MJ, Sowa NA, Taylor-Blake B, et al. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine [J]. Neuron. 2008;60(1):111\u201322.","journal-title":"Neuron"},{"issue":"14","key":"784_CR185","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1158\/0008-5472.CAN-07-1651","volume":"67","author":"IB Quintero","year":"2007","unstructured":"Quintero IB, Araujo CL, Pulkka AE, et al. Prostatic acid phosphatase is not a prostate specific target [J]. Cancer Res. 2007;67(14):6549\u201354.","journal-title":"Cancer Res"},{"issue":"3","key":"784_CR186","first-page":"295","volume":"4","author":"TJ Graddis","year":"2011","unstructured":"Graddis TJ, McMahan CJ, Tamman J, et al. Prostatic acid phosphatase expression in human tissues [J]. Int J Clin Exp Pathol. 2011;4(3):295\u2013306.","journal-title":"Int J Clin Exp Pathol"},{"key":"784_CR187","doi-asserted-by":"publisher","first-page":"485743","DOI":"10.1155\/2014\/485743","volume":"2014","author":"GG Yegutkin","year":"2014","unstructured":"Yegutkin GG, Auvinen K, Karikoski M, et al. Consequences of the lack of CD73 and prostatic acid phosphatase in the lymphoid organs [J]. Mediators Inflamm. 2014;2014.","journal-title":"Mediators Inflamm."},{"issue":"3","key":"784_CR188","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, et al. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses [J]. Cancer Cell. 2016;30(3):391\u2013403.","journal-title":"Cancer Cell"},{"key":"784_CR189","doi-asserted-by":"crossref","unstructured":"Yang R, Elsaadi S, Misund K, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade [J]. J Immunother Cancer. 2020;8(1):e000610.","DOI":"10.1136\/jitc-2020-000610"},{"issue":"4","key":"784_CR190","first-page":"43-","volume":"8","author":"DM Direnzo","year":"2020","unstructured":"Direnzo DM, Narasappa N, Piovesan D, et al. The dual A(2a)R\/A(2b)R antagonist AB928 reverses adenosine-mediated immune suppression and inhibits tumor growth in vivo [J]. Cancer Immunology Res. 2020;8(4):43-.","journal-title":"Cancer Immunology Res."},{"key":"784_CR191","doi-asserted-by":"crossref","unstructured":"Direnzo D, Zhang K, Cho S, et al. A2bR contributes to adenosine-mediated immunosuppression, which is relieved by the dual A2aR\/A2bR antagonist AB928 [J]. J Immunother Cancer. 2019;7(Suppl 1):282.","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A162"},{"key":"784_CR192","doi-asserted-by":"crossref","unstructured":"Direnzo D, Piovesan D, Tan J, et al. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression [J]. Cancer Immunol Res. 2019;7(2):183\u2013195.","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A162"},{"key":"784_CR193","doi-asserted-by":"crossref","unstructured":"Subudhi SK, Bendell JC, Carducci MA, et al. ARC-6: A phase 1b\/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC) [J]. J Clin Oncol. 2021;39(15_suppl):TPS5099.","DOI":"10.1200\/JCO.2021.39.15_suppl.5039"},{"issue":"1","key":"784_CR194","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy [J]. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"17","key":"784_CR195","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy [J]. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"issue":"6","key":"784_CR196","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","volume":"19","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Chen M, Xu D, et al. The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma [J]. Cell Mol Immunol. 2022;19(6):726\u201337.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"784_CR197","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies [J]. Nat Immunol. 2020;21(11):1346\u201358.","journal-title":"Nat Immunol"},{"key":"784_CR198","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade [J]. Drug Resist Updat. 2023;66:100907.","journal-title":"Drug Resist Updat."},{"issue":"17","key":"784_CR199","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1056\/NEJMc2119768","volume":"386","author":"AM Menzies","year":"2022","unstructured":"Menzies AM, Pires DA Silva I, Trojaniello C, et al. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab [J]. N Engl J Med. 2022;386(17):1668\u20139.","journal-title":"N Engl J Med."},{"issue":"2","key":"784_CR200","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy [J]. Cancer Cell. 2019;35(2):238-55.e6.","journal-title":"Cancer Cell"},{"issue":"20","key":"784_CR201","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard B, Pommey S, Smyth MJ, et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs [J]. Clin Cancer Res. 2013;19(20):5626\u201335.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"784_CR202","first-page":"172","volume":"4","author":"R Iannone","year":"2014","unstructured":"Iannone R, Miele L, Maiolino P, et al. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model [J]. Am J Cancer Res. 2014;4(2):172\u201381.","journal-title":"Am J Cancer Res"},{"key":"784_CR203","doi-asserted-by":"publisher","first-page":"120166","DOI":"10.1016\/j.lfs.2021.120166","volume":"288","author":"F Karoon Kiani","year":"2022","unstructured":"Karoon Kiani F, Izadi S, Ansari Dezfouli E, et al. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models [J]. Life Sci. 2022;288:120166.","journal-title":"Life Sci."},{"issue":"5","key":"784_CR204","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, Milenkovski N, Henderson MA, et al. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses [J]. Cancer Immunol Res. 2015;3(5):506\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"784_CR205","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","volume":"67","author":"RD Leone","year":"2018","unstructured":"Leone RD, Sun IM, Oh MH, et al. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models [J]. Cancer Immunology Immunotherapy. 2018;67(8):1271\u201384.","journal-title":"Cancer Immunology Immunotherapy."},{"issue":"8","key":"784_CR206","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M, et al. Blocking Antibodies Targeting the CD39\/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies [J]. Cell Rep. 2019;27(8):2411-25 e9.","journal-title":"Cell Rep."},{"key":"784_CR207","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","volume":"368","author":"T Zhang","year":"2024","unstructured":"Zhang T, Tai Z, Miao F, et al. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances [J]. J Control Release. 2024;368:372\u201396.","journal-title":"J Control Release."},{"key":"784_CR208","doi-asserted-by":"crossref","unstructured":"Kirtane K, Elmariah H, Chung C H, et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead [J]. J Immunother Cancer. 2021;9(7):e002838.","DOI":"10.1136\/jitc-2021-002723"},{"issue":"12","key":"784_CR209","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","volume":"21","author":"JD Chan","year":"2021","unstructured":"Chan JD, Lai J, Slaney CY, et al. Cellular networks controlling T cell persistence in adoptive cell therapy [J]. Nat Rev Immunol. 2021;21(12):769\u201384.","journal-title":"Nat Rev Immunol"},{"key":"784_CR210","doi-asserted-by":"crossref","unstructured":"Neo S Y, Xu S, Chong J, et al. Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer [J]. J Immunother Cancer. 2023;11(4):e006296.","DOI":"10.1136\/jitc-2022-006434"},{"key":"784_CR211","doi-asserted-by":"publisher","first-page":"108667","DOI":"10.1016\/j.pharmthera.2024.108667","volume":"259","author":"R Ramapriyan","year":"2024","unstructured":"Ramapriyan R, Vykunta VS, Vandecandelaere G, et al. Altered cancer metabolism and implications for next-generation CAR T-cell therapies [J]. Pharmacol Ther. 2024;259:108667.","journal-title":"Pharmacol Ther."},{"issue":"3","key":"784_CR212","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s42255-024-00976-2","volume":"6","author":"SJ McPhedran","year":"2024","unstructured":"McPhedran SJ, Carleton GA, Lum JJ. Metabolic engineering for optimized CAR-T cell therapy [J]. Nat Metab. 2024;6(3):396\u2013408.","journal-title":"Nat Metab"},{"issue":"17","key":"784_CR213","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1158\/0008-5472.CAN-17-0395","volume":"77","author":"J Reinhardt","year":"2017","unstructured":"Reinhardt J, Landsberg J, Schmid-Burgk JL, et al. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy [J]. Cancer Res. 2017;77(17):4697\u2013709.","journal-title":"Cancer Res"},{"issue":"2","key":"784_CR214","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"42","author":"DD Klysz","year":"2024","unstructured":"Klysz DD, Fowler C, Malipatlolla M, et al. Inosine induces stemness features in CAR-T cells and enhances potency [J]. Cancer Cell. 2024;42(2):266-82 e8.","journal-title":"Cancer Cell."},{"issue":"3","key":"784_CR215","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, Henderson MA, Giuffrida L, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy [J]. J Clin Invest. 2017;127(3):929\u201341.","journal-title":"J Clin Invest"},{"issue":"1","key":"784_CR216","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","volume":"39","author":"E Masoumi","year":"2020","unstructured":"Masoumi E, Jafarzadeh L, Mirzaei HR, et al. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells [J]. J Exp Clin Cancer Res. 2020;39(1):49.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"784_CR217","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, Sek K, Henderson MA, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy [J]. Nat Commun. 2021;12(1):3236.","journal-title":"Nat Commun"},{"key":"784_CR218","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.iotech.2023.100394","volume":"19","author":"JR Cox","year":"2023","unstructured":"Cox JR, Jennings M, Lenahan C, et al. Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies [J]. Immunooncol Technol. 2023;19:100394.","journal-title":"Immunooncol Technol."},{"issue":"6","key":"784_CR219","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","volume":"70","author":"D Jin","year":"2010","unstructured":"Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression [J]. Cancer Res. 2010;70(6):2245\u201355.","journal-title":"Cancer Res"},{"issue":"8","key":"784_CR220","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","volume":"67","author":"RD Leone","year":"2018","unstructured":"Leone RD, Sun IM, Oh MH, et al. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models [J]. Cancer Immunol Immunother. 2018;67(8):1271\u201384.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"784_CR221","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","volume":"127","author":"M Seifert","year":"2022","unstructured":"Seifert M, Benmebarek MR, Briukhovetska D, et al. Impact of the selective A2(A)R and A2(B)R dual antagonist AB928\/etrumadenant on CAR T cell function [J]. Br J Cancer. 2022;127(12):2175\u201385.","journal-title":"Br J Cancer"},{"issue":"4","key":"784_CR222","doi-asserted-by":"publisher","first-page":"C799","DOI":"10.1152\/ajpcell.1989.256.4.C799","volume":"256","author":"GH Moser","year":"1989","unstructured":"Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog-blood [J]. Am J Physiol. 1989;256(4):C799\u2013806.","journal-title":"Am J Physiol"},{"key":"784_CR223","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.coph.2020.08.003","volume":"53","author":"SB Willingham","year":"2020","unstructured":"Willingham SB, Hotson AN, Miller RA. Targeting the A2AR in cancer; early lessons from the clinic [J]. Curr Opin Pharmacol. 2020;53:126\u201333.","journal-title":"Curr Opin Pharmacol"},{"key":"784_CR224","doi-asserted-by":"crossref","unstructured":"Turiello R, Capone M, Giannarelli D, et al. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy [J]. J Immunother Cancer. 2020;8(2):e001689.","DOI":"10.1136\/jitc-2020-001689"},{"key":"784_CR225","doi-asserted-by":"crossref","unstructured":"Augustin RC, Leone RD, Naing A, et al. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy [J]. J Immunother Cancer. 2022;10(2):e003905.","DOI":"10.1136\/jitc-2021-004089"},{"key":"784_CR226","doi-asserted-by":"crossref","unstructured":"Sun Y, Liu C, He L. Adenosine A2A receptor antagonist SCH58261 improves the cognitive function in Alzheimer's disease model mice through activation of Nrf2 via an autophagy-dependent pathway [J]. Antioxid Redox Signal. 2024;41(16-18):1117\u201333.","DOI":"10.1089\/ars.2023.0455"},{"key":"784_CR227","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1038\/ncomms11915","volume":"7","author":"DA Viana","year":"2016","unstructured":"Viana DA, Silva S, Haberl MG, Zhang P, et al. Early synaptic deficits in the APP\/PS1 mouse model of Alzheimer\u2019s disease involve neuronal adenosine A2A receptors [J]. Nat Commun. 2016;7:11915.","journal-title":"Nat Commun."},{"key":"784_CR228","doi-asserted-by":"crossref","unstructured":"Illes P, Ulrich H, Chen JF, et al. Purinergic receptors in cognitive disturbances [J]. Neurobiol Dis. 2023;185:106229.","DOI":"10.1016\/j.nbd.2023.106229"},{"key":"784_CR229","doi-asserted-by":"publisher","first-page":"104570","DOI":"10.1016\/j.nbd.2019.104570","volume":"132","author":"FQ Gon\u00e7alves","year":"2019","unstructured":"Gon\u00e7alves FQ, Lopes JP, Silva HB, et al. Synaptic and memory dysfunction in a \u03b2-amyloid model of early Alzheimer\u2019s disease depends on increased formation of ATP-derived extracellular adenosine [J]. Neurobiol Dis. 2019;132:104570.","journal-title":"Neurobiol Dis."},{"key":"784_CR230","doi-asserted-by":"crossref","unstructured":"Houthuys E, MarillieR R, Deregnaucourt T, et al. EOS100850, an insurmountable and non-brain penetrant A(2A) receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics [J]. Cancer Res. 2018;78(13_suppl):CT180.","DOI":"10.1158\/1538-7445.AM2018-LB-291"},{"key":"784_CR231","doi-asserted-by":"crossref","unstructured":"Ploeg E M, Samplonius D F, Xiong X, et al. Bispecific antibody CD73xEGFR more selectively inhibits the CD73\/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR [J]. J Immunother Cancer. 2023;11(9):e006765.","DOI":"10.1136\/jitc-2023-006837"},{"issue":"1","key":"784_CR232","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"JJ Shi","year":"2017","unstructured":"Shi JJ, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities [J]. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"784_CR233","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12951-023-01826-1","volume":"21","author":"P Shi","year":"2023","unstructured":"Shi P, Cheng Z, Zhao K, et al. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics [J]. J Nanobiotechnology. 2023;21(1):103.","journal-title":"J Nanobiotechnology"},{"key":"784_CR234","doi-asserted-by":"publisher","first-page":"107871","DOI":"10.1016\/j.pharmthera.2021.107871","volume":"226","author":"P Jain","year":"2021","unstructured":"Jain P, Kathuria H, Momin M. Clinical therapies and nano drug delivery systems for urinary bladder cancer [J]. Pharmacol Ther. 2021;226:107871.","journal-title":"Pharmacol Ther."},{"key":"784_CR235","doi-asserted-by":"publisher","first-page":"216397","DOI":"10.1016\/j.canlet.2023.216397","volume":"574","author":"M Xu","year":"2023","unstructured":"Xu M, Li S. Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment [J]. Cancer Lett. 2023;574:216397.","journal-title":"Cancer Lett."},{"issue":"Pt 2","key":"784_CR236","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.semcancer.2022.01.008","volume":"86","author":"AR Afshari","year":"2022","unstructured":"Afshari AR, Sanati M, Mollazadeh H, et al. Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways [J]. Semin Cancer Biol. 2022;86(Pt 2):860\u201372.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"784_CR237","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.apsb.2024.03.012","volume":"14","author":"F Gao","year":"2024","unstructured":"Gao F, Wu Y, Wang R, et al. Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer [J]. Acta Pharm Sin B. 2024;14(6):2685\u201397.","journal-title":"Acta Pharm Sin B"},{"key":"784_CR238","doi-asserted-by":"publisher","first-page":"118747","DOI":"10.1016\/j.carbpol.2021.118747","volume":"276","author":"H Mousazadeh","year":"2022","unstructured":"Mousazadeh H, Bonabi E, ZarghamI N. Stimulus-responsive drug\/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy [J]. Carbohydr Polym. 2022;276:118747.","journal-title":"Carbohydr Polym."},{"key":"784_CR239","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcis.2022.02.050","volume":"616","author":"X Kuang","year":"2022","unstructured":"Kuang X, Wang Z, Luo Z, et al. Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma [J]. J Colloid Interface Sci. 2022;616:189\u2013200.","journal-title":"J Colloid Interface Sci"},{"key":"784_CR240","doi-asserted-by":"crossref","unstructured":"Zhao Y, Xie Z, Deng Y, et al. Photothermal nanobomb blocking metabolic adenosine-A2AR potentiates infiltration and activity of T cells for robust antitumor immunotherapy [J]. Chem Eng J. 2022;450:138139.","DOI":"10.1016\/j.cej.2022.138139"},{"issue":"13","key":"784_CR241","doi-asserted-by":"publisher","first-page":"12087","DOI":"10.1021\/acsnano.2c11403","volume":"17","author":"Q Chen","year":"2023","unstructured":"Chen Q, Chen J, Zhang Q, et al. Combining High-Z Sensitized Radiotherapy with CD73 Blockade to Boost Tumor Immunotherapy [J]. ACS Nano. 2023;17(13):12087\u2013100.","journal-title":"ACS Nano"},{"key":"784_CR242","doi-asserted-by":"crossref","unstructured":"Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer [J]. Adv Drug Deliv Rev. 2022;182:114113.","DOI":"10.1016\/j.addr.2022.114113"},{"key":"784_CR243","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jconrel.2022.09.029","volume":"351","author":"CS Yuan","year":"2022","unstructured":"Yuan CS, Teng Z, Yang S, et al. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy [J]. J Control Release. 2022;351:255\u201371.","journal-title":"J Control Release"},{"issue":"2","key":"784_CR244","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2009.09.011","volume":"290","author":"M Saito","year":"2010","unstructured":"Saito M, Yaguchi T, Yasuda Y, et al. Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A(1) adenosine receptors [J]. Cancer Lett. 2010;290(2):211\u20135.","journal-title":"Cancer Lett"},{"issue":"3","key":"784_CR245","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1159\/000341447","volume":"30","author":"T Kanno","year":"2012","unstructured":"Kanno T, Nakano T, Fujita Y, et al. Adenosine induces apoptosis in SBC-3 human lung cancer cells through A(3) adenosine receptor-dependent AMID upregulation [J]. Cell Physiol Biochem. 2012;30(3):666\u201377.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"784_CR246","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/jcp.25873","volume":"233","author":"MH Kazemi","year":"2018","unstructured":"Kazemi MH, Mohseni SR, Hojjat-Farsangi M, et al. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer [J]. J Cell Physiol. 2018;233(3):2032\u201357.","journal-title":"J Cell Physiol"},{"issue":"4","key":"784_CR247","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, Ngiow SF, Gao Y, et al. A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment [J]. Cancer Res. 2018;78(4):1003\u201316.","journal-title":"Cancer Res"},{"key":"784_CR248","doi-asserted-by":"crossref","unstructured":"Borodovsky A, Barbon CM, Wang Y, et al. Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity [J]. J Immunother Cancer. 2020;8(2):e000417.","DOI":"10.1136\/jitc-2019-000417"},{"issue":"2","key":"784_CR249","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1136\/annrheumdis-2020-217007","volume":"81","author":"ZW Gao","year":"2022","unstructured":"Gao ZW, Wang X, Lin F, et al. Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum [J]. Ann Rheum Dis. 2022;81(2):e30.","journal-title":"Ann Rheum Dis"},{"key":"784_CR250","doi-asserted-by":"crossref","unstructured":"Zhulai G, Oleinik E, Shibaev M, et al. Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer [J]. Biomolecules. 2022;12(3):418.","DOI":"10.3390\/biom12030418"},{"issue":"12","key":"784_CR251","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-21-0340","volume":"81","author":"L Wang","year":"2021","unstructured":"Wang L, Londono LM, Cowell J, et al. Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors [J]. Cancer Res. 2021;81(12):3319\u201332.","journal-title":"Cancer Res"},{"issue":"26","key":"784_CR252","doi-asserted-by":"publisher","first-page":"eadg3736","DOI":"10.1126\/sciadv.adg3736","volume":"9","author":"OS Sarkar","year":"2023","unstructured":"Sarkar OS, Donninger H, Al Rayyan N, et al. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy [J]. Sci Adv. 2023;9(26):eadg3736.","journal-title":"Sci Adv."},{"issue":"7","key":"784_CR253","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s42255-020-0219-4","volume":"2","author":"T Wang","year":"2020","unstructured":"Wang T, Gnanaprakasam JNR, Chen X, et al. Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction [J]. Nat Metab. 2020;2(7):635\u201347.","journal-title":"Nat Metab"},{"issue":"2","key":"784_CR254","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"42","author":"DD Klysz","year":"2024","unstructured":"Klysz DD, Fowler C, Malipatlolla M, et al. Inosine induces stemness features in CAR-T cells and enhances potency [J]. Cancer Cell. 2024;42(2):266-82.e8.","journal-title":"Cancer Cell"},{"issue":"1","key":"784_CR255","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1038\/s41467-022-33116-z","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Jiang L, Yu L, et al. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses [J]. Nat Commun. 2022;13(1):5413.","journal-title":"Nat Commun"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:03:39Z","timestamp":1747663419000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":255,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00784-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}